Table 1b.

Evaluation of transmission-blocking activity by immunization and DFA.

	Challenge	Mean change in infection intensity	Mean change in prevalence
Regime 1: Pvs25-FhCMB Abisco-100	Pb Pvs25DR3 challenge (n = 5)	65.3% a	54.1% b
	Pb 2.34 challenge (n = 5)	6.5%	-6.6%
Regime 2: Pvs25-FhCMB Alhydrogel	Pb Pvs25DR3 challenge (n = 5)	56.6% a	51.6% b
	Pb 2.34 challenge (n = 5)	-1.5%	-7.6%
Regime 3: Pvs25-ChAd63 - MVA	Pb Pvs25DR3 challenge (n = 5)	38.0%	35.6% b
	Pb 2.34 challenge (n = 5)	-18.7%	0.42%
Regime 4: Pvs25-ChAd63 - Pvs25-FhCMB -Abisco-100	Pb Pvs25DR3 challenge (n = 5)	74.5% a	68.3% b
	Pb 2.34 challenge (n = 5)	-2.4%	-4.9%